Ribociclib

Overview

Ribociclib is a selective cyclin-dependent kinase inhibitor used in the treatment of breast cancer. It works by inhibiting cyclin D1/CDK4 and CDK6, blocking retinoblastoma protein phosphorylation and cell cycle progression.

API suppliers (2)

Suppliers of Ribociclib backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• MSN Laboratories Private LimitedIndia2 active DMF
• FRESENIUS KABI ONCOLOGY LTD

Patent & exclusivity (US)

Per the FDA Orange Book (1 approved US product), the latest listed US patent on Ribociclib expires 13 Oct 2036 and exclusivity 17 Mar 2028. Generic API sourcing typically opens up once these lapse.

Therapeutic areas